Enveric Biosciences, Inc. (ENVB) Income Statement
ENVB 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsENVB revenue and net income
ENVB profit margins
ENVB growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ENVB quarterly EPS vs estimates
Enveric Biosciences beat the analyst EPS estimate in 2 of the last 5 quarters. Next report: November 13, 2026.
ENVB income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $39.9M | $39.9M | $43.0M | $48.6M | $36.1M |
| Cost of revenue | $200,858 | $337,489 | $408,030 | $435,201 | $681,612 | $120,872 | $31.8M | $34.0M | $38.4M | $29.6M |
| Gross profit | −$200,858 | −$337,489 | −$408,030 | −$435,201 | −$681,612 | −$120,872 | $8.2M | $9.0M | $10.2M | $6.5M |
| Research & development | $2.8M | $2.8M | $7.3M | $8.0M | $4.8M | $174,083 | — | — | — | — |
| Sales, general & admin | $5.8M | $6.5M | $8.9M | $11.6M | $20.5M | $5.4M | $12.2M | $10.8M | $18.5M | $9.0M |
| Total operating expenses | $8.6M | $9.3M | $16.0M | $19.5M | $25.3M | $5.5M | $14.5M | $13.7M | $21.7M | $10.3M |
| Operating income | −$8.8M | −$9.6M | −$16.4M | −$20.0M | −$25.9M | −$5.6M | −$6.3M | −$7.1M | −$12.0M | −$5.4M |
| Interest income | — | $219 | $3,708 | — | — | — | — | — | — | — |
| Interest expense | $106 | — | $3,708 | $5,249 | $10,316 | $445,250 | $691,138 | $729,896 | $575,039 | $751,074 |
| Income before taxes | −$8.8M | −$9.6M | −$17.3M | −$20.0M | −$56.4M | −$6.9M | −$5.2M | −$10.5M | −$11.5M | −$6.5M |
| Income taxes | $3.4M | $8,930 | $28,913 | −$1.5M | −$7.5M | −$477,731 | $388,657 | $6.3M | −$2.4M | −$3.7M |
| Net income | −$12.1M | −$9.6M | −$17,292 | −$18.5M | −$49.0M | −$6.9M | −$5.6M | −$16.9M | −$9.1M | −$2.8M |
| EBITDA | −$8.6M | −$9.2M | −$16.9M | −$19.5M | −$55.7M | −$6.3M | −$2.3M | −$6.9M | −$7.7M | −$4.4M |
| EPS (diluted) | −$31.08 | −$200.03 | −$743.25 | −$2734.40 | −$2971.38 | — | — | −$2208.10 | — | −$87953.73 |
| Gross margin | — | — | — | — | — | −0.3% | 20.4% | 20.9% | 21.1% | 18.1% |
| Operating margin | — | — | — | — | — | −14.1% | −15.8% | −16.6% | −24.6% | −14.9% |
| Net margin | — | — | — | — | — | −17.2% | −14.0% | −39.3% | −18.7% | −7.7% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $340,376 | $0 | $0 | $0 | $647,092 | $0 |
| Cost of revenue | $36,826 | $37,240 | $39,485 | $40,369 | $39,980 | $81,024 | $82,487 | $84,814 | $84,779 | $85,409 | $84,682 | $95,839 |
| Gross profit | −$36,826 | −$37,240 | −$39,485 | −$40,369 | −$39,980 | −$81,024 | −$82,487 | −$84,814 | −$84,779 | −$85,409 | −$84,682 | −$95,839 |
| Research & development | $1.4M | $345,969 | $372,178 | $402,417 | $1.3M | $746,371 | $1.1M | $762,717 | $515,501 | $458,155 | $1.4M | $1.4M |
| Sales, general & admin | $1.6M | $1.2M | $1.8M | $1.4M | $1.2M | $1.4M | $2.0M | $1.2M | $1.3M | $1.9M | $2.8M | $2.0M |
| Total operating expenses | $3.0M | $1.6M | $2.2M | $1.8M | $2.5M | $2.1M | $3.1M | $2.0M | $1.8M | $2.4M | $2.3M | $3.4M |
| Operating income | −$3.0M | −$1.6M | −$2.2M | −$1.9M | −$2.5M | −$2.2M | −$3.2M | −$2.1M | −$1.9M | −$2.5M | −$2.4M | −$3.4M |
| Interest expense | $292 | $303 | $250 | $274 | $132 | — | — | $217 | $35 | $696 | $544 | $2,237 |
| Income before taxes | −$3.0M | −$1.6M | −$2.2M | −$1.9M | −$2.5M | −$2.2M | −$3.1M | −$2.1M | −$1.9M | −$2.5M | −$3.4M | −$2.8M |
| Income taxes | — | — | — | $1.5M | — | — | $7,199 | — | $1 | $1,731 | $22,318 | $6,595 |
| Net income | −$3.0M | −$1.6M | −$2.2M | −$1.9M | −$2.5M | −$2.2M | −$3.2M | −$2.1M | −$1.9M | −$2.5M | −$3.4M | −$2.8M |
| EBITDA | −$3.0M | −$1.6M | −$2.2M | −$1.8M | −$2.5M | −$2.1M | −$3.1M | −$2.0M | −$1.8M | −$2.4M | −$3.3M | −$2.7M |
| EPS (diluted) | −$0.76 | −$1.08 | −$3.81 | −$10.81 | −$11.65 | −$4.82 | −$2.03 | −$43.20 | −$45.00 | −$109.80 | −$1.47 | −$287.12 |
| Gross margin | — | — | — | — | — | — | −24.2% | — | — | — | −13.1% | — |
| Operating margin | — | — | — | — | — | — | −932.4% | — | — | — | −368.5% | — |
| Net margin | — | — | — | — | — | — | −926.8% | — | — | — | −531.0% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ENVB's financial statements (latest annual report filed March 27, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ENVB financial results
Enveric Biosciences reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $12.1 million. Diluted earnings per share came to −$31.08.
See the ENVB stock overview for the latest quote and news, or the ENVB chart for price history and technical indicators.
ENVB income statement FAQ
Does Enveric Biosciences have revenue?
Enveric Biosciences reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Enveric Biosciences profitable?
No. Enveric Biosciences reported a net loss of $12.1 million in fiscal 2025.
How much does Enveric Biosciences spend on research and development?
Enveric Biosciences spent $2.8 million on research and development in fiscal 2025.
What are Enveric Biosciences's earnings per share?
Enveric Biosciences earned $-31.08 per diluted share in fiscal 2025, compared with $-200.03 a year earlier.
When will Enveric Biosciences report its next earnings?
Enveric Biosciences is expected to report results for the quarter ending September 30, 2026 on November 13, 2026.
When does Enveric Biosciences's fiscal year end?
Enveric Biosciences's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 27, 2026.